Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods - 6 August 2021

Overview

The Therapeutic Goods Act 1989 was enacted to provide for the regulation of therapeutic goods in Australia, ensuring that these products are safe, of high quality, and effective for their intended use. This Act was introduced to address the need for a comprehensive legal framework governing the manufacture, supply, and advertising of therapeutic goods, including medicines, medical devices, and blood products. The Therapeutic Goods Administration (TGA), an agency within the Department of Health, administers the Act and is responsible for its enforcement. The policy objective of the Act is to protect public health by ensuring that therapeutic goods are of acceptable quality and do not pose a risk to the health and safety of consumers. On 6 August 2021, the TGA, through Katherine Clark as the delegate of the Secretary, published a notice under section 41 of the Therapeutic Goods Act 1989. This notice detailed the revocation of the licence of ATR Packing Services Pty Ltd, which held a Licence to Manufacture Therapeutic Goods. The revocation was carried out at the request of the manufacturer, reflecting the Act’s provisions that allow for the revocation of licences under certain conditions, such as when the manufacturer deems it appropriate. This action underscores the TGA’s role in overseeing compliance and ensuring that only entities meeting the necessary standards are authorised to manufacture therapeutic goods in Australia.

Scope and Application

The Therapeutic Goods Act 1989 applies to various entities and individuals involved in the manufacture, supply, importation, and advertisement of therapeutic goods in Australia. This encompasses a wide range of products, including medicines, medical devices, and blood and blood components. The Act applies to all persons and entities conducting activities related to these therapeutic goods, including manufacturers, suppliers, importers, and advertisers. The Act's jurisdiction extends across the Commonwealth of Australia, with the Therapeutic Goods Administration (TGA) being the federal regulator responsible for ensuring the safety, quality, and efficacy of therapeutic goods within the country. The scope of the Act includes the licensing and regulation of therapeutic goods, with certain exclusions and exemptions noted within the legislation. Additionally, the Act allows for the creation of subordinate instruments, which can extend or restrict the application of the primary Act. These instruments may provide further detail on specific aspects of the legislation, such as the requirements for manufacturing licences or the classification of therapeutic goods.

Key Provisions

The Therapeutic Goods Act 1989, in particular section 41(1)(d), provides the Secretary with the authority to revoke a licence to manufacture therapeutic goods. This legislative provision enables the Secretary to withdraw a licence upon written notice when deemed necessary. In this instance, the revocation of the licence held by ATR Packing Services Pty Ltd (Licence No. MI-2015-LI-13859-1), located at 3 Reaghs Farm Road, Minto, NSW, 2566, was executed by Katherine Clark, the Delegate of the Secretary of the Department of Health Therapeutic Goods Administration, and the revocation was made at the request of the manufacturer. This formal notice was published in the Gazette on 6 August 2021. The Act imposes several obligations on entities holding a licence to manufacture therapeutic goods. These entities must adhere to stringent quality and safety standards to ensure that the therapeutic goods produced are safe, effective, and of high quality. The licence holder is responsible for maintaining records, conducting inspections, and ensuring compliance with all relevant regulations and standards. The revocation of a licence under section 41(1)(d) typically occurs when the manufacturer requests it, potentially due to a range of factors including a decision to cease operations, failure to meet regulatory requirements, or other reasons deemed appropriate by the manufacturer and the Therapeutic Goods Administration. Breaches of the provisions set out in the Therapeutic Goods Act 1989 can lead to significant legal consequences. While specific offences and penalties are not detailed in the notice of revocation, the Act generally provides for both civil and criminal penalties. For instance, manufacturing therapeutic goods without a valid licence, or contravening any condition of a licence, can result in substantial fines and even imprisonment. The exact penalties depend on the nature and severity of the breach, but they can be severe, reflecting the critical importance of adhering to the Act’s requirements to protect public health and safety.